Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults with Respiratory Syncytial Virus

Authors and Affiliations:

(1) Kevin C. Ma, PhD
 Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

(2) Diya Surie, MD
 Coronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia

(3) Yuwei Zhu, MD, MS
 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee

(4) Carlos G. Grijalva, MD, MPH
 Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee

(5) Paul W. Blair, MD, MHS
 Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University Medical Center, Nashville, Tennessee

(6) Basmah Safdar, MD, MSc
 Yale University School of Medicine, New Haven, Connecticut

(7) Adit A. Ginde, MD, MPH
 Department of Emergency Medicine, University of Colorado School of Medicine, Aurora, Colorado

(8) Ithan D. Peltan, MD, MSc
 Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, Salt Lake City, Utah

(9) Samuel M. Brown, MD, MS
 Department of Pulmonary/Critical Care Medicine, Intermountain Medical Center, Murray, Utah and University of Utah, Salt Lake City, Utah

(10) Manjusha Gaglani, MBBS
 Baylor Scott and White Health, Temple and Dallas, Texas, and Baylor College of Medicine, Temple, Texas

44
45   (11) Shekhar Ghamande, MD
46   Baylor Scott and White Health, Baylor College of Medicine, Temple, Texas
47
48   (12) Cristie Columbus, MD
49   Baylor, Scott & White Health, Texas A&M University College of Medicine, Dallas, Texas
50
51   (13) Nicholas M. Mohr, MD, MS
52   University of Iowa, Iowa City, Iowa
53
54   (14) Kevin W. Gibbs, MD
55   Department of Medicine, Wake Forest School of Medicine, Winston-Salem, North
56   Carolina
57
58   (15) David N. Hager, MD, PhD
59   Department of Medicine, Johns Hopkins University School of Medicine, Baltimore,
60   Maryland
61
62   (16) Matthew E. Prekker, MD, MPH
63   Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis,
64   Minnesota
65
66   (17) Michelle N. Gong, MD, MS
67   Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine,
68   Bronx, New York
69
70   (18) Amira Mohamed, MD
71   Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine,
72   Bronx, New York
73
74   (19) Nicholas J. Johnson, MD
75   Department of Emergency Medicine and Division of Pulmonary, Critical Care and Sleep
76   Medicine, University of Washington, Seattle, Washington
77
78   (20) Jay S. Steingrub, MD
79   Department of Medicine, Baystate Medical Center, Springfield, Massachusetts
80
81   (21) Akram Khan, MBBS
82   Department of Medicine, Oregon Health and Sciences University, Portland, Oregon
83
84   (22) Catherine L. Hough, MD
85   Department of Medicine, Oregon Health and Sciences University, Portland
86
87   (23) Abhijit Duggal, MD, MPH, MSc

88   Department of Medicine, Cleveland Clinic, Cleveland, Ohio
89
90   (24) Alexandra June Gordon, MD
91   Department of Emergency Medicine, Stanford University School of Medicine, Stanford,
92   California
93
94   (25) Nida Qadir, MD
95   Department of Medicine, University of California-Los Angeles, Los Angeles, California
96
97   (26) Steven Y. Chang, MD, PhD
98   Department of Medicine, University of California-Los Angeles, Los Angeles, California
99
100   (27) Christopher Mallow, MD, MHS
101   Department of Medicine, University of Miami, Miami, Florida
102
103   (28) Laurence W. Busse, MD, FCCM
104   Department of Medicine, Emory University, Atlanta, Georgia
105
106   (29) Jennie H. Kwon, DO, MSCI
107   Department of Medicine, Washington University, St. Louis, Missouri
108
109   (30) Matthew C. Exline, MD, MPH
110   Department of Medicine, The Ohio State University, Columbus, Ohio
111
112   (31) Ivana A. Vaughn, PhD, MPH
113   Department of Public Health Sciences, Henry Ford Health, Detroit, Michigan
114
115   (32) Mayur Ramesh, MD
116   Division of Infectious Diseases, Henry Ford Health, Detroit, Michigan
117
118   (33) Adam S. Lauring, MD, PhD
119   Departments of Internal Medicine and Microbiology and Immunology, University of
120   Michigan, Ann Arbor, Michigan
121
122   (34) Emily T. Martin, PhD, MPH
123   School of Public Health, University of Michigan, Ann Arbor, Michigan
124
125   (35) Aleda M. Leis, PhD, MS
126   School of Public Health, University of Michigan, Ann Arbor, Michigan
127
128   (36) Jarrod M. Mosier, MD
129   Department of Emergency Medicine, University of Arizona, Tucson, Arizona
130
(37) Estelle S. Harris, MD

Department of Medicine, University of Utah, Salt Lake City, Utah

(38) Adrienne Baughman

Department of Emergency Medicine, Vanderbilt University Medical Center, Nashville,

Tennessee

(39) Cassandra Johnson, MS

Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee

(40) Jonathan D. Casey, MD

Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

(41) Natasha Halasa, MD, MPH

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee

(42) James D. Chappell, MD, PhD

Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee

(43) Nathaniel Lewis, PhD

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers

for Disease Control and Prevention (CDC), Atlanta, Georgia

(44) Sascha Ellington, PhD, MSPH

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers

for Disease Control and Prevention (CDC), Atlanta, Georgia

(45) Wesley H. Self, MD, MPH

Vanderbilt Institute for Clinical and Translational Research, and Department of

Emergency Medicine, Vanderbilt University Medical Center, Nashville, Tennessee

(46) Fatimah S. Dawood, MD

Coronavirus and Other Respiratory Viruses Division, National Center for Immunization

and Respiratory Diseases, Centers for Disease Control and Prevention (CDC), Atlanta,

Georgia

(47) For the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network*

*A full list of collaborators in the IVY Network is shown in the Supplementary Materials.

174 **Word count: 3000**

175 **Correspondence:** Kevin C. Ma (tra3@cdc.gov), Centers for Disease Control and Prevention,

176 1600 Clifton Road, NE, Atlanta, Georgia, USA

Key points

Question: How does multimorbidity influence risk of severe outcomes among adults hospitalized with RSV?

Findings: In this cohort study of 1,111 U.S. adults hospitalized with RSV during 2022–2024, approximately one in four patients aged 18–59 and ≥60 years had a profile of frequent heart failure, chronic kidney disease, diabetes and elevated risk of ICU admission and acute organ failure. Adults aged ≥60 years with chronic pulmonary disease with home oxygen dependence had the highest risk for ICU admission and acute organ failure.

Meaning: The role of distinct multimorbidity profiles in increasing severe RSV disease risk warrants further attention.

Abstract

Importance: Adults hospitalized with acute respiratory infections, including respiratory syncytial virus (RSV), often have multiple underlying conditions. Few data are available on the combined effect of concurrent underlying conditions on risk of severe outcomes from RSV disease among inpatients.

Objective: To identify underlying condition profiles associated with increased risk of severe outcomes among adults hospitalized with RSV.

Design: We applied Bayesian profile regression, an outcome-informed statistical clustering model, to identify profiles of conditions associated with increased risk of RSV-associated severe outcomes separately among adults aged 18–59 and ≥60 years. Seventeen underlying conditions were selected after excluding those with rare prevalence (≤1%) or high pairwise tetrachoric correlation (≥0.7).

Setting: 26 hospitals in 20 U.S. states

Participants: Prospectively enrolled adults hospitalized with RSV disease admitted January 2022–July 2024

Main Outcomes and Measures: Risks of ICU admission, acute organ failure, and invasive mechanical ventilation (IMV) or death

Results: We analyzed data from 1111 adults hospitalized with RSV (median age [IQR] = 66 [53–75]). Among 397 adults aged 18–59 years, two profiles were identified characterized by (1) fewer underlying conditions ("minimal prevalence" profile; 308 cases [78%]; median number of conditions = 1; IQR 1–2) with a posterior median ICU admission risk of 20.5% (95% credible interval = [16.1□25.0]), and (2) a cardiorenal/diabetes profile (89 cases [22%]) with frequent heart failure, chronic kidney disease, diabetes and increased ICU admission risk (37.1% [27.3□47.6]). Among 714 adults aged ≥60 years, four profiles were identified: (1) minimal condition prevalence (460 cases [64%]; ICU admission risk = 21.6% [18.4□25.5]), (2) cardiorenal/diabetes (183 cases [26%]; 27.3% [21.4□33.6]), (3) hematologic malignancy and transplant receipt (52 cases [7%]; 11.8% [5.7□21.0]), and (4) chronic pulmonary disease with home oxygen dependence (19 cases [3%]; 44.0% [24.5□65.8]). Similar differences in risk were observed for acute organ failure and IMV or death.

220   **Conclusion and Relevance:** Distinct underlying condition profiles with varying risks of severe

221   outcomes were identified in adults hospitalized with RSV. These findings could support

222   recognition of high-risk patients to inform RSV prevention strategies and suggest that the role of

223   multimorbidity in increasing severe RSV disease risk warrants further attention.

Introduction

Respiratory syncytial virus (RSV) is associated with an estimated 123,000–193,000 hospitalizations and 5,000–9,000 deaths annually in US adults, with almost half of all hospitalizations occurring in adults aged ≥75 years [1,2]. Illness severity among adults hospitalized with RSV is similar to severity observed in hospitalized patients with COVID-19 and influenza [3–6]. Risk factors for RSV hospitalization include older age and underlying conditions (e.g., heart failure, chronic obstructive pulmonary disease [COPD], chronic kidney disease [CKD], severe obesity, and diabetes) [6–13], but there are few data on risk factors for in-hospital outcomes. Additionally, adult patients hospitalized with RSV often present with multiple underlying medical conditions [7,14–16], and few studies have assessed the combined effect of specific sets of conditions on risk of in-hospital outcomes.

RSV vaccines were first approved and recommended for older adults in the US in 2023. In 2024, RSV vaccination guidelines were updated to recommend a single vaccine dose for all adults aged ≥75 years and adults aged 60–74 years with medical conditions that confer increased risk of severe disease [1,17,18]. Expanded licensure for some younger adults has been approved by the FDA [19] and recommendations for some groups of adults aged <60 years may be considered in the future [20]. Characterizing combinations of underlying conditions associated with increased risk of severe RSV disease in adults could inform prevention strategy recommendations [1,17]. Here, we use Bayesian profile regression, a statistical clustering model, to identify profiles of underlying conditions associated with increased risk of severe outcomes among adults hospitalized with RSV during January 2022 through July 2024.

Methods

Design and data collection

The Investigating Respiratory Viruses in the Acutely Ill (IVY) network is a multicenter inpatient surveillance network comprising 26 hospitals in 20 U.S. states used for assessing vaccine effectiveness and clinical epidemiology [3,21–24] (Supplementary Materials). During January 2022–July 2024, sites prospectively enrolled inpatients aged ≥18 years who met an acute respiratory illness case definition and had clinical testing performed for SARS-CoV-2, influenza viruses, or RSV (Supplementary Methods). Nasal swab surveillance specimens were

additionally collected from all enrolled patients and tested at Vanderbilt University Medical

Center for these viruses. Medical records were reviewed by trained personnel who abstracted

demographic and clinical data, including underlying conditions and in-hospital outcomes.

Receipt of RSV vaccine was identified by a combination of electronic medical records, state or

city vaccine registries, and plausible self-reported data.

Enrolled inpatients were included if they had RSV infection confirmed by clinical or surveillance

testing of a respiratory specimen collected within 10 days of symptom onset and 3 days of

hospital admission. Patients were excluded if they had co-detection of influenza viruses or

SARS-CoV-2 (n = 158), missing underlying conditions (n = 64), or missing outcomes (n = 35).

We stratified the cohort by patient age group (18–59 and ≥60 years) to account for age-

dependent risk and prevalence of conditions.

Underlying conditions and severe in-hospital outcomes

We included underlying condition risk factors for severe RSV disease among older adults

defined by the Advisory Committee on Immunization Practices [18]. To restrict to the most

informative conditions, we removed conditions with high tetrachoric correlation (≥0.7) [25] with

other conditions or rare (≤1%) prevalence, resulting in seventeen conditions (Supplementary

Methods). Clinical severity was characterized using severe outcomes from presentation to the

first of hospital discharge, patient death, or hospital day 28 [3]. These outcomes included (1)

intensive care unit (ICU) admission, (2) acute organ failure, defined as either respiratory failure

(new receipt of high-flow nasal canula, noninvasive ventilation, or invasive mechanical

ventilation [IMV]), cardiovascular failure (vasopressor use), or kidney failure (new receipt of

kidney replacement therapy), and (3) a composite of IMV or death (Supplementary Methods).

Descriptive statistical analyses

We evaluated overall differences using Fisher's exact test for categorical variables and the

Mann-Whitney test for continuous variables. For assessing counts of conditions, conditions

were dichotomized, and only severe obesity was included among all body mass index (BMI)

categories.

Bayesian profile regression

We applied Bayesian profile regression, a statistical clustering method that comprises an

assignment submodel that assigns individuals to a condition profile, and a disease submodel

that evaluates association of profiles with the outcome. These submodels are jointly fitted in a

Bayesian paradigm, enabling the outcome variable to influence profile membership

(Supplementary Methods) [26–29]. We conducted Bayesian profile regression in R (version

4.4.1) separately for the two age groups and three outcome variables using the PReMiuM

package [27]. We assessed dependency on initial random profile allocations and outcome

variable used (Supplementary Methods). Condition prevalence and severe outcome risk were

described using median posterior probabilities and 95% Bayesian equal-tailed credible intervals

(i.e., spanning from the 2.5^{th} to 97.5^{th} percentile) [30]. We characterized profiles based on

conditions that differed in prevalence among patients within a profile compared to all patients in

the age group, as indicated when profile condition prevalence credible intervals excluded

empirical prevalence. Differences in outcome risks relative to the "minimal prevalence"

reference profile (defined in Results) were assessed using risk ratios ($RR_{Profile}$); credible intervals

that excluded 1 were interpreted as evidence under the Bayesian framework for a difference in

outcome risk. We also calculated the posterior probability $P(RR_{Profile} > 1)$ to quantify the strength

of evidence for increased risk.

Poisson regression

We compared Bayesian profile regression results to frequentist Poisson regression estimates of

adjusted risk ratios for individual conditions ($RR_{Poisson}$). To improve estimation for rare outcomes

and conditions, we used Firth bias-reduced Poisson regression with robust error variances and

the Morel correction as implemented in the *firthb* R package (Supplementary Methods) [31,32].

Models were fit separately for the two age groups and three outcome variables. After applying

the Benjamini–Hochberg procedure for multiple testing, two-sided adjusted *P*-values $\leq$ .05

were interpreted as evidence under a frequentist framework that a condition was significantly

associated with a change in outcome risk.

Ethical review

This activity was reviewed by CDC, deemed not research, and was conducted consistent with

applicable federal law and CDC policy. (45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42

U.S.C. §241(d); 5 U.S.C. §552a; 44 U.S.C. §3501 et seq).

Results

A total of 1111 RSV inpatients were included from 26 hospitals in 20 U.S. states, comprising

397 adults aged 18–59 and 714 adults aged ≥60. RSV inpatients had a median age of 66 years

(IQR 54–75) and the majority were female (n = 600; 54.0%) and non-Hispanic White (n = 576;

51.8%) (Table). Hospitalization dates ranged from January 17, 2022, through July 5, 2024, and

most patients (57.5%) were enrolled during the Sept 21, 2023☐July 5, 2024 enrollment period.

Ten adults aged ≥60 years (1.4% of adults aged ≥60 years) received an RSV vaccination, and

46 patients (4.8% among 968 patients with available data) received ribavirin antiviral treatment

during hospitalization. Underlying conditions were prevalent, with 303 patients (27.3%) having

one condition, 274 (24.7%) having two, 224 (20.2%) having three, and 194 (17.5%) having four

or more with increasing burden by age (Supplementary Figure 1, Supplementary Table 1,

Supplementary Table 3).

Adults aged 18-59 years

Among 397 RSV patients aged 18–59 years (median age = 49 years [IQR 35–55]), 96 (24.2%)

were admitted to the ICU, 118 (29.7%) experienced acute organ failure, and 32 (8.1%) received

IMV or died (Table). Underlying conditions were reported for 346 (87.2%) patients, with the most

common conditions being diabetes (n = 109; 27.5%), asthma (n = 96; 24.2%), CKD (n = 87;

21.9%), and heart failure (n = 83; 20.9%) (Figure 1). Patients admitted to the ICU more

frequently had severe obesity (25.0% vs. 14.3%; $P = 0.003$) and 4 or more underlying

conditions (28.1% vs. 8.3%; Fisher's $P = 0.003$). The conditions with the highest positive

correlations were heart failure and CKD (tetrachoric correlation = 0.51), CKD and solid organ or

hematopoietic cell transplant receipt (0.46), and hematologic malignancy and transplant receipt

(0.44) (Supplementary Figure 2).

Using Bayesian profile regression, we identified two patient profiles. Patients with the first profile

constituted 78% (n = 308) of the cohort; we termed this the *minimal prevalence* profile as

patients had fewer conditions than overall patients in this age group (median number = 1 [IQR

1–2]; Supplementary Table 1) and 95% credible intervals for condition prevalences included or

were lower than empiric prevalences (Figure 2A). Patients with the second profile constituted

the remaining 22% (n = 89) of the cohort and exhibited increased multimorbidity (median

number of conditions = 3 [IQR 3–4]). The prevalences of heart failure (posterior median [95%

credible interval] = 47.7% [36.9□58.7]), diabetes (41.3% [31.8□51.1]), and CKD with (29.6%

[19.9□40.5]) and without (22.9% [14.9□32.3]) end-stage renal disease were increased relative

to their empiric prevalences. We termed this the *cardiorenal and diabetes* profile as the majority

(70.8%) of patients had at two or more of these three conditions.

Patients with the cardiorenal and diabetes profile had elevated risk of ICU admission (37.1%

[27.3□47.6]; relative risk $RR_{Profile}$ = 1.81 [1.26□2.56]) compared to patients with the minimal

prevalence profile (20.5% [16.1□25.0]) (Figure 3). Relative risks of acute organ failure (37.2%

[28.1□46.4]; $RR_{Profile}$ = 1.37 [1.00□1.82]) and IMV or death (10.9% [5.7□17.7]; $RR_{Profile}$ = 1.51

[0.70□2.88]) were also elevated, though credible intervals for IMV or death did not exclude the

null (Supplementary Table 2). Patients with the minimal prevalence profile tended to be slightly

younger (median age = 48 years [IQR 34–54]) compared to patients with the cardiorenal and

diabetes profile (51 years [IQR 46–56]; Mann-Whitney *P* <0.001) (Supplementary Figure 3).

Adults aged ≥60 years

Among 714 RSV patients aged ≥60 (median age = 72 years [IQR 66–80]), 164 patients (23.0%)

were admitted to the ICU, 225 (31.5%) experienced acute organ failure, and 70 (9.8%) received

IMV or died. Underlying conditions were reported for 649 (90.9%) patients, and the most

common were diabetes (n = 254; 35.6%), COPD (n = 235; 32.9%), heart failure (n = 217;

30.4%), and CKD (n = 195; 27.3%) (Figure 1). Patients admitted to the ICU more frequently had

severe obesity (12.8% vs 8.9%; Fisher's *P* <0.001) and 4 or more underlying conditions (28.0%

vs. 17.5%; Fisher's *P* = 0.004) (Table). The most positively correlated conditions were

hematologic malignancy and transplant receipt (0.699), CKD and heart failure (0.44), and CKD

and diabetes (0.38) (Supplementary Figure 2).

We identified four profiles using Bayesian profile regression. Profile one (*minimal prevalence*, as

for younger adults) comprised 460 (64%) patients with relatively few conditions (median number

= 1 [IQR 1–2]; Supplementary Table 3) and condition prevalences similar to empiric prevalence

(Figure 2B). Profile two (*cardiorenal and diabetes*) comprised 183 patients (26%) with increased

multimorbidity (median number of conditions = 4 [IQR 3–4]) and higher prevalence of diabetes

(57.1% [49.6–64.4]), heart failure (52.5% [45.2–59.7]), and CKD with (17.0% [11.5–23.4]) and

without (39.8% [32.0–47.8]) end-stage renal disease; 87% of patients in this profile had two or

more of these conditions. Profile three comprised 52 patients (7%; median number of conditions

= 3 [IQR 2–4]) with higher prevalence of hematologic malignancy (45.4% [29.5–62.4]) and

transplant receipt (46.2% [31.7–60.0]); we termed this the *hematologic malignancy* profile.

Profile four comprised the remaining 19 patients (3%; median number of conditions = 4 [IQR 3–

5]) who had increased prevalence of COPD (70.0% [42.9–88.0]) and other pulmonary

conditions with home oxygen dependence (66.7% [34.3–91.8]; 15 of 19 patients had pulmonary

hypertension and 4 had pulmonary fibrosis), indicative of severe chronic pulmonary disease with

home oxygen dependence.

Patients with the severe chronic pulmonary disease profile experienced the highest ICU

admission risk (posterior median [95% credible interval] = 44.0% [24.5–65.8]), followed by the

cardiorenal and diabetes (27.3% [21.4–33.6]), minimal prevalence (21.6% [18.4–25.5]), and

hematologic malignancy profiles (11.8% [5.7–21.0]) (Figure 3). Relative to the minimal

prevalence profile, patients with the severe chronic pulmonary disease profile had a higher risk

of ICU admission ($RR_{Profile}$ = 2.03 [1.11–3.12]) and acute organ failure (1.90 [1.15–2.65])

(Supplementary Table 2). Patients with the cardiorenal and diabetes profile had a higher risk of

ICU admission (1.26 [0.96–1.62]), acute organ failure (1.25 [0.99–1.56]), and IMV or death

(2.00 [1.31–3.04]); credible intervals included the null for the first two outcomes. Patients with

the hematologic malignancy profile had a decreased risk of ICU admission (0.55 [0.26–0.98]).

Compared to all other patients, patients in the hematologic malignancy group more frequently

received ribavirin antiviral treatment (37.2% vs. 1.7% among patients with available data;

Fisher's *P* <0.001) (Supplementary Table 3).

Individual risk conditions

Among adults aged 18–59 years, using Poisson regression to evaluate individual conditions

associated with the three outcomes, only COPD without home oxygen use was associated with

increased risk of acute organ failure ($RR_{Poisson}$ = 1.27, 95% confidence interval = [1.11, 1.45];

Benjamini-Hochberg adjusted *P*-value = 0.016) (Figure 4, Supplementary Figure 4). This

association persisted stratifying within Bayesian inpatient profiles, and the highest organ failure

risk was observed among patients with the cardiorenal and diabetes profile and COPD

(Supplementary Table 4). Among adults aged ≥60 years, only COPD with home oxygen

dependence was associated with increased risk of acute organ failure ($RR_{Poisson}$ = 1.25 [1.12,

1.39]; Benjamini-Hochberg adjusted *P*-value = 0.001) (Figure 4, Supplementary Figure 5).

Discussion

In this prospective, multicenter analysis of >1,100 adults hospitalized with RSV, we found that

90% of patients had at least one underlying condition and almost two thirds had multiple. These

conditions partitioned into two profiles for adults aged 18–59 years and four for adults ≥60

years. Across both age groups, approximately one in four adults hospitalized with RSV had a

profile characterized by elevated prevalence of heart failure, diabetes, and CKD; patients with

this cardiorenal and diabetes profile had increased risk of multiple severe in-hospital outcomes.

Among adults aged ≥60 years, a rare severe chronic pulmonary disease with home oxygen

dependence profile was identified with the highest risk of ICU admission and acute organ

failure. A separate profile of patients with prevalent hematologic cancer or transplant receipt

was also observed with lower ICU admission risk. Using Poisson regression for individual risk

conditions, we also identified COPD as a risk factor for acute organ failure among adults in both

age groups [33]. Taken together, these findings identify subgroups of hospitalized adults with

increased risk of severe RSV disease, which could inform identification of high-risk patients,

healthcare provider counseling on RSV vaccination for currently eligible adults, and future RSV

prevention strategies for adults aged <60 years.

Few studies have examined multimorbidity among adults with RSV disease or characterized the

role of multimorbidity in increasing risk for severe outcomes. An analysis from a large US

population-based surveillance system found that adults with more chronic conditions had higher

rates of RSV hospitalization, with increases of 12-fold in adults aged 50–64 years with two

compared to no chronic conditions, 11-fold in adults aged 65–74 years, and 6-fold in adults

aged 75 and older [7]. This and other analyses have primarily categorized multimorbidity by

condition count or indices (e.g. Charlson or multimorbidity-weighted) [7,14–16]. Here, we

characterized specific concurrent conditions that jointly were associated with increased severity.

The triad of heart failure, CKD, and diabetes that we observed is a well-recognized clinical

profile among adults [34–37]. In a study of >87,000 adults with newly diagnosed heart failure in

the United Kingdom, 16% had concurrent CKD and diabetes and 52% had either condition;

patients with CKD, diabetes, or both had higher rates of hospitalizations and all-cause death

than those with heart failure alone [37]. Prior studies have also identified heart failure, CKD, and

diabetes as individual risk factors for RSV-associated hospitalizations in adults [8,13,38]. Our

study advances these findings by demonstrating the role of concurrent heart failure, CKD, and

diabetes as a combined risk factor for RSV severe outcomes.

This analysis used Bayesian profile regression, developed to address limitations of traditional

regression methods for modeling highly correlated covariates [26,39]. Here, we demonstrated

how Bayesian and traditional regression methods can provide complementary insights. Among

adults ≥60 years, COPD was identified as a primary risk factor using Poisson regression, in line

with prior studies [33]. Extending this, profile regression highlighted an infrequent subgroup of

COPD patients with home oxygen dependence and other concurrent pulmonary conditions

including pulmonary hypertension, a complication of COPD [40]. COPD was also identified as a

risk factor among younger adults, but did not coincide directly with a Bayesian profile. Instead,

we observed evidence for additive risk contributions from factors identified independently using

Bayesian and traditional regression, with elevated acute organ failure risk occurring among

cardiorenal and diabetes profile inpatients who also had COPD. These findings emphasize how

risk for severe outcomes can vary across a complex landscape of underlying conditions and

support the use of diverse methodologic approaches for risk factor characterization.

The findings in this report are subject to several limitations. First, the profiles generated by

Bayesian profile regression are exploratory, subject to misclassification, and require validation in

external cohorts. Second, our profile labels are simplified descriptors that may not fully capture

all features or causal risk factors. Third, we did not adjust for confounders beyond stratifying by

age, and limited sample sizes precluded further stratification. Fourth, this analysis conditions on

hospitalization and was not designed to assess risk factors for RSV-associated hospitalization.

Thus, although we found that inpatients aged ≥60 years with a hematologic malignancy profile

had a lower ICU admission risk than patients with a minimal prevalence profile, this finding does

not negate immunocompromising conditions as risk factors for RSV-associated hospitalization

[18]. The observed reduced risk of ICU admission may reflect differences in clinical thresholds

for hospital admission [13] or ribavirin antiviral treatment practices among patients with

hematologic malignancies or hematopoietic cell transplants [41,42], though further investigation

is needed to characterize these effects.

In summary, distinct profiles of underlying conditions with varying risks of severe outcomes were

observed among adults hospitalized with RSV. Adults hospitalized with RSV of all ages with a

cardiorenal and diabetes profile and adults aged ≥60 years with chronic pulmonary disease and

home oxygen dependence were at increased risk for severe outcomes. Findings from this

analysis suggest that the role of multimorbidity in increasing severe RSV disease risk warrants

further attention.

Acknowledgments.

Michael Melgar, MD (CDC) and Amadea Britton, MD (CDC) for critical input. Ryan Wiegand, PhD (CDC), Lan Shi, MS (VUMC), Trey McGonigle, MS (VUMC), and Bryan Blette, PhD (VUMC) for statistical review. These individuals were not compensated for their work.

Financial support. This work was supported by the United States Centers Disease Control and Prevention [contract 75D30122C14944].

Conflicts of interest. Jonathan D. Casey received a travel grant from Fisher and Paykel to attend a conference, outside the submitted work. James D. Chappell reports research support from Merck to study RSV epidemiology in hospitalized children, Amman, Jordan, outside the submitted work. Manjusha Gaglani reports grant funding from CDC, CDC-Abt Associates, and CDC-Westat, outside the submitted work. Michelle Gong received grant funding from NIH, CDC, participated as a scientific advisor for Regeneron, Novartis, Philips Healthcare, and was a section editor for UptoDate with Wolters Kulter, outside the submitted work. Carlos G. Grijalva has received consulting fees from Merck and GSK, and research support from CDC, NIH, FDA, AHRQ and Syneos Health, outside the submitted work. Natasha Halasa reports grant funding from Merck and participated as a one-time advisory board member for CSL-Seqirus, outside the submitted work. Catherine L. Hough reports additional funding provided for my work to my university from the NIH, outside the submitted work. Akram Khan received institutional research support from Dompe Pharmaceuticals, Direct Biologics, Roche, DoD and NIH and NHLBI for clinical trial participation, outside the submitted work. Adam S. Lauring receives research support from CDC, NIAID, FluLab, Roche (related to baloxavir), and consulting fees from Roche (related to Baloxavir), outside the submitted work. Ithan D. Peltan reports grant funding from NIH and funding to his institution from Bluejay Diagnostics and Novartis, outside the submitted work. Ivana A Vaughn receives funding through her institution for unrelated projects sponsored by eMaxHealth, Boehringer Ingelheim, Eli Lilly, and Pfizer, outside the submitted work.

References

1. Melgar M, Britton A, Roper LE, Talbot HK, Long SS, Kotton CN, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72: 793–801.

2. Havers FP, Whitaker M, Melgar M, Pham H, Chai SJ, Austin E, et al. Burden of respiratory syncytial virus-associated hospitalizations in US adults, October 2016 to September 2023. JAMA Netw Open. 2024;7: e2444756.

3. Surie D, Yuengling KA, DeCuir J, Zhu Y, Lauring AS, Gaglani M, et al. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Netw Open. 2024;7: e244954.

4. Landi SN, Garofalo DC, Reimbaeva M, Scott AM, Jiang L, Cappell K, et al. Hospitalization following outpatient diagnosis of respiratory syncytial virus in adults. JAMA Netw Open. 2024;7: e2446010.

5. Recto CG, Fourati S, Khellaf M, Pawlotsky J-M, De Prost N, Diakonoff H, et al. Respiratory syncytial virus vs influenza virus infection: Mortality and morbidity comparison over 7 epidemic seasons in an elderly population. J Infect Dis. 2024;230: 1130–1138.

6. Ambrosch A, Luber D, Klawonn F, Kabesch M. Focusing on severe infections with the respiratory syncytial virus (RSV) in adults: Risk factors, symptomatology and clinical course compared to influenza A / B and the original SARS-CoV-2 strain. J Clin Virol. 2023;161: 105399.

7. Woodruff R. Chronic Conditions as Risk Factors for RSV-Associated Hospitalization. Advisory Committee on Immunization Practices Meeting. 2024. Available: https://www.cdc.gov/acip/downloads/slides-2024-02-28-29/03-RSV-Adults-Woodruff-508.pdf

8. Kujawski SA, Whitaker M, Ritchey MD, Reingold AL, Chai SJ, Anderson EJ, et al. Rates of respiratory syncytial virus (RSV)-associated hospitalization among adults with congestive heart failure—United States, 2015–2017. Săndulescu O, editor. PLoS ONE. 2022;17: e0264890.

9. Linder KA, Malani PN. RSV Infection in Older Adults. JAMA. 2023;330: 1200.

10. Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366: l5021.

11. Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, et al. Acute Cardiac Events in Hospitalized Older Adults With Respiratory Syncytial Virus Infection. JAMA internal medicine. 2024. pp. 602–611.

12. Havers FP. Characteristics and outcomes among adults aged≥ 60 years hospitalized with laboratory-confirmed respiratory syncytial virus—RSV-NET, 12 states, July …. MMWR Morb Mortal Wkly Rep. 2023. Available: https://www.cdc.gov/mmwr/volumes/72/wr/mm7240a1.htm

13. Njue A, Nuabor W, Lyall M, Margulis A, Mauskopf J, Curcio D, et al. Systematic Literature
Review of Risk Factors for Poor Outcomes Among Adults With Respiratory Syncytial Virus
Infection in High-Income Countries. Open Forum Infect Dis. 2023;10: ofad513.

14. Begley KM, Leis AM, Petrie JG, Truscon R, Johnson E, Lamerato LE, et al. Epidemiology
of RSV in Adults and Children with Medically-Attended Acute Respiratory Illness over Three
Seasons. Clin Infect Dis. 2024. doi:10.1093/cid/ciae303

15. Malosh RE, Martin ET, Callear AP, Petrie JG, Lauring AS, Lamerato L, et al. Respiratory
syncytial virus hospitalization in middle-aged and older adults. J Clin Virol. 2017;96: 37–43.

16. Branche A, Ramesh M, Francis B. A narrative review of key risk factors for severe illness
following SARS-CoV-2, influenza virus, and respiratory syncytial virus infection. Infect Dis
Ther. 2025;14: 39–61.

17. Roper LE, Link-Gelles R, Surie D, DeCuir J, Zambrano LD, Prill MM, et al. A framework for
monitoring RSV prevention product effectiveness in the United States. Vaccine. 2025;45:
126633.

18. Britton A. Use of Respiratory Syncytial Virus Vaccines in Adults Aged ≥60 Years: Updated
Recommendations of the Advisory Committee on Immunization Practices — United States,
2024. MMWR Morb Mortal Wkly Rep. 2024;73. doi:10.15585/mmwr.mm7332e1

19. Office of the Commissioner. Respiratory Syncytial Virus (RSV). In: U.S. Food and Drug
Administration [Internet]. FDA; 25 Oct 2024 [cited 27 Feb 2025]. Available:
https://www.fda.gov/consumers/covid-19-flu-and-rsv/respiratory-syncytial-virus-rsv

20. Surie D, Melgar M, Britton A. ACIP Adult RSV Work Group Clinical Considerations. 2025.
Available: https://www.cdc.gov/acip/downloads/slides-2025-04-15-16/07-Surie-adult-RSV-
508.pdf

21. Ma KC, Surie D, Lauring AS, Martin ET, Leis AM, Papalambros L, et al. Effectiveness of
updated 2023-2024 (Monovalent XBB.1.5) COVID-19 vaccination against SARS-CoV-2
omicron XBB and BA.2.86/JN.1 lineage hospitalization and a comparison of clinical
severity-IVY network, 26 hospitals, October 18, 2023-March 9, 2024. Clin Infect Dis. 2024;
ciae405.

22. Surie D, Self WH, Zhu Y, Yuengling KA, Johnson CA, Grijalva CG, et al. RSV Vaccine
Effectiveness Against Hospitalization Among US Adults 60 Years and Older. JAMA. 2024
[cited 4 Sep 2024]. doi:10.1001/jama.2024.15775

23. Lauring AS, Edson C, Surie D, Dawood FS, Self WH, Lucero-Obusan C, et al. Genomic
characterization of RSV in the US by vaccination status. JAMA. 2025 [cited 10 Mar 2025].
doi:10.1001/jama.2025.1225

24. Link-Gelles R. Interim estimates of 2024–2025 COVID-19 vaccine effectiveness among
adults aged ≥18 years — VISION and IVY networks, September 2024–January 2025.
MMWR Morb Mortal Wkly Rep. 2025;74. doi:10.15585/mmwr.mm7406a1

25. Kaltenhauser J, Lee Y. Correlation coefficients for binary data in factor analysis. Geogr
Anal. 1976;8: 305–313.

26. Molitor J, Papathomas M, Jerrett M, Richardson S. Bayesian profile regression with an
584   application to the National Survey of Children's Health. Biostatistics. 2010;11: 484–498.

585   27. Liverani S, Hastie DI, Azizi L, Papathomas M, Richardson S. PReMiuM: An R package for
586   profile regression mixture models using Dirichlet processes. J Stat Softw. 2015;64: 1–30.

587   28. Rouanet A, Johnson R, Strauss M, Richardson S, Tom BD, White SR, et al. Bayesian
588   profile regression for clustering analysis involving a longitudinal response and explanatory
589   variables. Methodology (Gott). 2024;73: 314–339.

590   29. Papathomas M, Molitor J, Richardson S, Riboli E, Vineis P. Examining the joint effect of
591   multiple risk factors using exposure risk profiles: lung cancer in nonsmokers. Environ
592   Health Perspect. 2011;119: 84–91.

593   30. Hespanhol L, Vallio CS, Costa LM, Saragiotto BT. Understanding and interpreting
594   confidence and credible intervals around effect estimates. Braz J Phys Ther. 2019;23: 290–
595   301.

596   31. Uno S, Noma H, Gosho M. Firth-type penalized methods of the modified Poisson and least-
597   squares regression analyses for binary outcomes. Biom J. 2024;66: e202400004.

598   32. Zou G. A modified poisson regression approach to prospective studies with binary data. Am
599   J Epidemiol. 2004;159: 702–706.

600   33. Penders Y, Brusselle G, Falsey AR, Rohde G, Betancur E, Guardado ME, et al. Burden of
601   respiratory syncytial virus disease in adults with asthma and chronic obstructive pulmonary
602   disease: A systematic literature review. Curr Allergy Asthma Rep. 2025;25: 14.

603   34. Vijay K, Neuen BL, Lerma EV. Heart failure in patients with diabetes and chronic kidney
604   disease: Challenges and opportunities. Cardiorenal Med. 2022;12: 1–10.

605   35. Méndez Fernández AB, Vergara Arana A, Olivella San Emeterio A, Azancot Rivero MA,
606   Soriano Colome T, Soler Romeo MJ. Cardiorenal syndrome and diabetes: an evil pairing.
607   Front Cardiovasc Med. 2023;10: 1185707.

608   36. Tuegel C, Bansal N. Heart failure in patients with kidney disease. Br Heart J. 2017;103:
609   1848–1853.

610   37. Lawson CA, Seidu S, Zaccardi F, McCann G, Kadam UT, Davies MJ, et al. Outcome trends
611   in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK
612   over twenty years. EClinicalMedicine. 2021;32: 100739.

613   38. Branche AR, Saiman L, Walsh EE, Falsey AR, Sieling WD, Greendyke W, et al. Incidence
614   of respiratory syncytial virus infection among hospitalized adults, 2017-2020. Clin Infect Dis.
615   2022;74: 1004–1011.

616   39. Vatcheva KP, Lee M, McCormick JB, Rahbar MH. Multicollinearity in regression analyses
617   conducted in epidemiologic studies. Epidemiology (Sunnyvale). 2016;6. doi:10.4172/2161-
618   1165.1000227

619   40. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J.
620   2008;32: 1371–1385.

41.   Manothummetha K, Mongkolkaew T, Tovichayathamrong P, Boonyawairote R, Meejun T,
Srisurapanont K, et al. Ribavirin treatment for respiratory syncytial virus infection in patients
with haematologic malignancy and haematopoietic stem cell transplant recipients: a
systematic review and meta-analysis. Clin Microbiol Infect. 2023;29: 1272–1279.

42.   Farina F, Sannipoli D, Diral E, Mastaglio S, Oltolini C, Dell'Acqua R, et al. Impact of
Respiratory Syncytial Virus (RSV) on adult haematology oncology patients. J Infect.
2024;89: 106347.

Table. Characteristics of Patients Hospitalized with Respiratory Syncytial Virus by Age Group and Intensive Care Unit Admission Status — IVY Network, 26 Hospitals, January 2022–July 2024, N = 1111

	Overall (N = 1111)	Patients Aged 18–59 (N = 397)		Patients Aged ≥60 (N = 714)	
		No ICU admission (N = 301)	ICU admission (N = 96)	No ICU admission (N = 550)	ICU admission (N = 164)
Age					
Median (IQR)	66 (54, 75)	49 (35, 55)	48 (35, 55)	73 (66, 81)	71 (67, 77)
Sex					
Female	600 (54.0%)	162 (53.8%)	51 (53.1%)	310 (56.4%)	77 (47.0%)
Male	511 (46.0%)	139 (46.2%)	45 (46.9%)	240 (43.6%)	87 (53.0%)
Race/ethnicity					
Hispanic	181 (16.3%)	60 (19.9%)	17 (17.7%)	84 (15.3%)	20 (12.2%)
Non-Hispanic Black	261 (23.5%)	94 (31.2%)	28 (29.2%)	110 (20.0%)	29 (17.7%)
Non-Hispanic White	576 (51.8%)	123 (40.9%)	38 (39.6%)	322 (58.5%)	93 (56.7%)
Non-Hispanic, other race[a]	52 (4.7%)	14 (4.7%)	7 (7.3%)	16 (2.9%)	15 (9.1%)
Other[b]	41 (3.7%)	10 (3.3%)	6 (6.3%)	18 (3.3%)	7 (4.3%)
Enrollment period					
Jan 1, 2022–Aug 31, 2022	143 (12.9%)	45 (15.0%)	13 (13.5%)	63 (11.5%)	22 (13.4%)
Sept 1, 2022–Sept 20, 2023	329 (29.6%)	91 (30.2%)	32 (33.3%)	156 (28.4%)	50 (30.5%)
Sept 21, 2023–July 5, 2024	639 (57.5%)	165 (54.8%)	51 (53.1%)	331 (60.2%)	92 (56.1%)
RSV vaccination[c]	10 (0.9%)	-	-	7 (1.3%)	3 (1.8%)
Ribavirin administered[d]	46 (4.8%)	17 (6.6%)	3 (3.6%)	21 (4.3%)	5 (3.5%)
BMI category[e]					
Underweight	73 (6.6%)	14 (4.7%)	6 (6.3%)	38 (6.9%)	15 (9.1%)
Healthy weight	297 (26.7%)	73 (24.3%)	25 (26.0%)	146 (26.5%)	53 (32.3%)
Overweight	291 (26.2%)	63 (20.9%)	18 (18.8%)	172 (31.3%)	38 (23.2%)

		Patients Aged 18–59 (N = 397)		Patients Aged ≥60 (N = 714)	
	Overall (N = 1111)	No ICU admission (N = 301)	ICU admission (N = 96)	No ICU admission (N = 550)	ICU admission (N = 164)
Class 1 or 2 obesity	313 (28.2%)	108 (35.9%)	23 (24.0%)	145 (26.4%)	37 (22.6%)
Severe obesity	137 (12.3%)	43 (14.3%)	24 (25.0%)	49 (8.9%)	21 (12.8%)
Number of underlying conditions associated with RSV disease[f]					
0	116 (10.4%)	40 (13.3%)	11 (11.5%)	55 (10.0%)	10 (6.1%)
1	303 (27.3%)	96 (31.9%)	26 (27.1%)	140 (25.5%)	41 (25.0%)
2	274 (24.7%)	81 (26.9%)	14 (14.6%)	142 (25.8%)	37 (22.6%)
3	224 (20.2%)	59 (19.6%)	18 (18.8%)	117 (21.3%)	30 (18.3%)
≥4	194 (17.5%)	25 (8.3%)	27 (28.1%)	96 (17.5%)	46 (28.0%)
ICU admission	260 (23.4%)	-	-	-	-
Acute organ failure[g]	343 (30.9%)	38 (12.6%)	80 (83.3%)	91 (16.5%)	134 (81.7%)
IMV or death[h]	102 (9.2%)	1 (0.3%)	31 (32.3%)	11 (2.0%)	59 (36.0%)

Percentages are column percentages.

[a] "Non-Hispanic, other race" includes American Indian or Alaska Native, Asian, and Native Hawaiian or other Pacific Islander categories, which were combined because of small counts.

[b] "Other" includes patients who self-reported their race and ethnicity as "other" and those for whom race and ethnicity were unknown.

[c] RSV vaccination status was determined from electronic medical records, immunization registries, and self-report and was defined as RSV vaccine receipt 14 days or more before illness onset. Adults aged 18–59 years were not eligible for vaccination during the analytic period.

[d] A total of 143 patients (12.9%) were missing data on ribavirin use. The percentage of patients receiving ribavirin was calculated based on nonmissing data.

[e] BMI categories were defined using the following BMI (kg/m^2) ranges: underweight (less than 18.5); healthy weight (18.5 to less than 25); overweight (25 to less than 30); class 1 or 2 obesity (30 to less than 40); class 3 i.e. severe obesity (40 or greater).

[f] For counts of underlying conditions, only severe obesity was included among all BMI categories to align with vaccine eligibility guidelines [18]. Other underlying conditions associated with RSV severe disease and included in counts were diabetes, chronic kidney disease (including end-stage renal disease), heart failure, atherosclerotic cardiovascular disease, asthma, chronic obstructive pulmonary disease (with or without home oxygen use), other pulmonary conditions (cystic fibrosis, pulmonary fibrosis, or pulmonary hypertension; with or without home oxygen use), solid organ or hematopoietic cell transplant receipt, active hematologic malignancy, active solid tumor malignancy, HIV infection, autoimmune or autoinflammatory conditions (systemic lupus erythematosus, rheumatoid arthritis, psoriasis, polymyositis, mixed connective tissue disease, polymyalgia rheumatica, inflammatory bowel disease, or other autoimmune diseases), dementia (only included for adults aged ≥60), neuromuscular conditions (muscular dystrophy, cerebral palsy, hemiplegia, paraplegia, or anterolateral sclerosis), liver disease (including cirrhosis), and sickle cell disease or thalassemia (only included for adults aged 18☐59).

[g] Acute organ failure defined as a composite of respiratory failure (new receipt of high-flow nasal canula, non-invasive mechanical ventilation, or IMV), cardiovascular failure (use of vasopressors), or kidney failure (new receipt of kidney replacement therapy).

[h] Among adults aged 18☐59, 31 received IMV and 9 died; among adults aged ≥60, 53 received IMV and 29 died.

Abbreviations: RSV = respiratory syncytial virus; ICU = intensive care unit; BMI = body mass index; IMV = intensive mechanical ventilation.

Figure 1. Prevalence of Underlying Conditions[a] by Age Group Among Patients Hospitalized with Respiratory Syncytial Virus — IVY Network, 26 Hospitals, January 2022–July 2024, N = 1111

* The prevalence of dementia in adults aged 18–59 and sickle cell or thalassemia in adults aged ≥60 was <1%.

[a] BMI categories were defined using the following BMI (kg/m^2) ranges: underweight (less than 18.5); healthy weight (18.5 to less than 25); overweight (25 to less than 30); class 1 or 2 obesity (30 to less than 40); class 3 i.e. severe obesity (40 or greater). Underlying conditions potentially associated with RSV disease included underweight, overweight, class 1 or 2 obesity, severe obesity, diabetes, chronic kidney disease (including end-stage renal disease), heart failure, atherosclerotic cardiovascular disease, asthma, chronic

obstructive pulmonary disease (with or without home oxygen use), other pulmonary conditions (cystic fibrosis, pulmonary fibrosis, or pulmonary hypertension; with or without home oxygen use), solid organ or hematopoietic cell transplant receipt, active hematologic malignancy, active solid tumor malignancy, HIV infection, autoimmune or autoinflammatory conditions (systemic lupus erythematosus, rheumatoid arthritis, psoriasis, polymyositis, mixed connective tissue disease, polymyalgia rheumatica, inflammatory bowel disease, or other autoimmune diseases), dementia (only included for adults aged ≥60), neuromuscular conditions (muscular dystrophy, cerebral palsy, hemiplegia, paraplegia, or anterolateral sclerosis), liver disease (including cirrhosis), and sickle cell disease or thalassemia (only included for adults aged 18□59).

[b] Complicated conditions include COPD with home oxygen use, other pulmonary conditions with home oxygen use, liver disease with cirrhosis, and chronic kidney disease with end stage renal disease as indicated by chronic renal replacement therapy.

Abbreviations: ICU = intensive care unit; IMV = intensive mechanical ventilation; BMI = body mass index; CVD = cardiovascular disease; COPD = chronic obstructive pulmonary disease; IBD = inflammatory bowel disease.

Figure 2. Prevalence and 95% Credible Intervals of Underlying Conditions[a] By Bayesian Profiles[b] of Patients A) Aged 18–59 (N = 397) and B) ≥60 (N = 714) Hospitalized with Respiratory Syncytial Virus — IVY Network, 26 Hospitals, January 2022–July 2024

Closed circles and error bars are median prevalence estimates and 95% Bayesian equal-tailed credible intervals from the posterior distribution, respectively. Open circles indicate empirical prevalence of the condition among all patients within the age group. Among adults in both age groups, profile 1 represents the minimal prevalence profile and 2 represents the cardiorenal and diabetes profile. Among adults aged ≥60, profile 3 represents the hematologic malignancy profile, and 4 represents the severe chronic pulmonary disease with home oxygen dependence profile.

[a] BMI categories were defined using the following BMI (kg/m^2) ranges: underweight (less than 18.5); healthy weight (18.5 to less than 25); overweight (25 to less than 30); class 1 or 2 obesity (30 to less than 40); class 3 i.e. severe obesity (40 or greater). Underlying conditions potentially associated with RSV disease included underweight, overweight, class 1 or 2 obesity, severe obesity, diabetes, chronic kidney disease (including end-stage renal disease), heart failure, atherosclerotic cardiovascular disease, asthma, chronic obstructive pulmonary disease (with or without home oxygen use), other pulmonary conditions (cystic fibrosis, pulmonary fibrosis, or pulmonary hypertension; with or without home oxygen use), solid organ or hematopoietic cell transplant receipt, active hematologic malignancy, active solid tumor malignancy, HIV infection, autoimmune or autoinflammatory conditions (systemic lupus erythematosus, rheumatoid arthritis, psoriasis, polymyositis, mixed connective tissue disease, polymyalgia rheumatica, inflammatory bowel disease, or other autoimmune diseases), dementia (only included for adults aged ≥60), neuromuscular conditions (muscular dystrophy, cerebral palsy, hemiplegia, paraplegia, or anterolateral sclerosis), liver disease (including cirrhosis), and sickle cell disease or thalassemia (only included for adults aged 18□59).

[b] Bayesian profile regression is an outcome variable-informed statistical clustering approach that comprises an assignment submodel (assigns individuals to a condition profile) and a disease submodel (evaluates association of profiles with the outcome variable); the two submodels are jointly fitted in a Bayesian paradigm, enabling the outcome variable to influence profile membership.

Abbreviations: ICU = intensive care unit; IMV = intensive mechanical ventilation; BMI = body mass index; CVD = cardiovascular disease; COPD = chronic obstructive pulmonary disease; IBD = inflammatory bowel disease.

Figure 3. Risk of Severe Outcomes[a] and 95% Credible Intervals Among Bayesian Profiles[b] of Patients Hospitalized with Respiratory Syncytial Virus Aged 18–59 (N = 397; A–C) and ≥60 (N = 714; D–F) Years — IVY Network, 26 Hospitals, January 2022–July 2024

Posterior distributions are depicted by equal-area density plots with taller regions indicating greater probability density. Median posterior distribution estimates are represented by the colored vertical line and error bars are 95% Bayesian equal-tailed credible

intervals. Among adults in both age groups, profile 1 represents the minimal prevalence profile and 2 represents the cardiorenal and diabetes profile. Among adults aged ≥60, profile 3 represents the hematologic malignancy profile, and 4 represents the severe chronic pulmonary disease with home oxygen dependence profile.

[a] Severe outcomes included ICU admission, acute organ failure, and invasive mechanical ventilation (IMV) or death. Acute organ failure was defined as a composite of respiratory failure (new receipt of high-flow nasal canula, non-invasive mechanical ventilation, or IMV), cardiovascular failure (use of vasopressors), or kidney failure (new receipt of kidney replacement therapy).

[b] Bayesian profile regression is an outcome variable-informed statistical clustering approach that comprises an assignment submodel (assigns individuals to a condition profile) and a disease submodel (evaluates association of profiles with the outcome variable); the two submodels are jointly fitted in a Bayesian paradigm, enabling the outcome variable to influence profile membership.

Abbreviations: ICU = intensive care unit; IMV = intensive mechanical ventilation.

Figure 4. Heatmap of *P*-value (Opacity) Versus Risk[a] (Hue) of Severe In-Hospital Outcomes[b] by Underlying Condition[c] Among Patients Hospitalized with Respiratory Syncytial Virus Estimated Using Poisson Regression — IVY Network, 26 Hospitals, January 2022–July 2024

1.25 1.4

ᴲ among
dition

* indicates two-sided *P*-values ☐≤☐.05 unadjusted for multiple testing

** indicates two-sided *P*-values ≤ 0.05 adjusted for multiple testing correction using the Benjamini-Hochberg procedure with a false-discovery rate of 0.05

[a] Risk ratios were estimated using Firth bias-reduced Poisson regression models with robust error variances [31] separately for the two age groups and three outcome variables. Hue indicates the sign and magnitude of the point estimate of the risk ratio (blues for decreased risk, reds for increased risk) and opacity indicates *P*-value (increasing opacity for decreasing *P*-values).

[b] Severe outcomes included ICU admission, acute organ failure, and invasive mechanical ventilation (IMV) or death. Acute organ failure was defined as a composite of respiratory failure (new receipt of high-flow nasal canula, non-invasive mechanical ventilation, or IMV), cardiovascular failure (use of vasopressors), or kidney failure (new receipt of kidney replacement therapy).

[c] BMI categories were defined using the following BMI (kg/m^2) ranges: underweight (less than 18.5); healthy weight (18.5 to less than 25); overweight (25 to less than 30); class 1 or 2 obesity (30 to less than 40); class 3 i.e. severe obesity (40 or greater). Underlying conditions potentially associated with RSV disease included underweight, overweight, class 1 or 2 obesity, severe obesity, diabetes, chronic kidney disease (including end-stage renal disease), heart failure, atherosclerotic cardiovascular disease, asthma, chronic obstructive pulmonary disease (with or without home oxygen use), other pulmonary conditions (cystic fibrosis, pulmonary fibrosis, or pulmonary hypertension; with or without home oxygen use), solid organ or hematopoietic cell transplant receipt, active hematologic malignancy, active solid tumor malignancy, HIV infection, autoimmune or autoinflammatory conditions (systemic lupus erythematosus, rheumatoid arthritis, psoriasis, polymyositis, mixed connective tissue disease, polymyalgia rheumatica, inflammatory bowel disease, or other autoimmune diseases), dementia (only included for adults aged ≥60), neuromuscular conditions (muscular dystrophy, cerebral palsy, hemiplegia, paraplegia, or anterolateral sclerosis), liver disease (including cirrhosis), and sickle cell disease or thalassemia (only included for adults aged 18 59).

Abbreviations: ICU = intensive care unit; IMV = intensive mechanical ventilation; BMI = body mass index; CVD = cardiovascular disease; COPD = chronic obstructive pulmonary disease; IBD = inflammatory bowel disease.